Molecular Characterization of Acquired Resistance to KRAS(G12C)–EGFR Inhibition in Colorectal Cancer

With the combination of KRAS(G12C) and EGFR inhibitors, KRAS is becoming a druggable target in colorectal cancer. However, secondary resistance limits its efficacy. Using cell lines, patient-derived xenografts, and patient samples, we detected a heterogeneous pattern of putative resistance alteratio...

Descripción completa

Detalles Bibliográficos
Autores principales: Yaeger, Rona, Mezzadra, Riccardo, Sinopoli, Jenna, Bian, Yu, Marasco, Michelangelo, Kaplun, Esther, Gao, Yijun, Zhao, HuiYong, Paula, Arnaud Da Cruz, Zhu, Yingjie, Perez, Almudena Chaves, Chadalavada, Kalyani, Tse, Edison, Chowdhry, Sudhir, Bowker, Sydney, Chang, Qing, Qeriqi, Besnik, Weigelt, Britta, Nanjangud, Gouri J., Berger, Michael F., Der-Torossian, Hirak, Anderes, Kenna, Socci, Nicholas D., Shia, Jinru, Riely, Gregory J., Murciano-Goroff, Yonina R., Li, Bob T., Christensen, James G., Reis-Filho, Jorge S., Solit, David B., de Stanchina, Elisa, Lowe, Scott W., Rosen, Neal, Misale, Sandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Research Briefs
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827113/
https://www.ncbi.nlm.nih.gov/pubmed/36355783
http://dx.doi.org/10.1158/2159-8290.CD-22-0405

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827113/
https://www.ncbi.nlm.nih.gov/pubmed/36355783
http://dx.doi.org/10.1158/2159-8290.CD-22-0405

Ejemplares similares